In a 1996 Merck-funded trial, a single oral dose of MK-677 increased 24-hour growth hormone secretion by 97% in healthy elderly subjects , and that effect was sustained over weeks of daily use without injections.
🔑 At a Glance
- What it is: Non-peptide ghrelin receptor agonist , triggers your pituitary to release GH, taken by mouth
- How it works: Binds GHS-R1a receptors in the hypothalamus and pituitary , same receptor activated by the hunger hormone ghrelin
- Key advantage: Oral dosing , no reconstitution, no syringes, once daily at bedtime
- IGF-1 elevation: 40-72% sustained increase documented across multiple human trials
- Standard dose: 25mg/day, taken at bedtime on an empty stomach
- Main side effects: Water retention, increased appetite, fatigue, and fasting glucose elevation
- Not a steroid: Does not suppress testosterone or natural hormone production at standard doses
- Cycle length: 8-12 weeks on, followed by a break
MK-677 occupies a strange corner of the peptide world , technically not a peptide at all, yet it works through the same receptor as ghrelin and produces GH elevations that rival injectable secretagogues. That oral bioavailability is what makes it so interesting. This guide covers how it works, what the clinical data actually shows, real side effect profiles, and how it stacks up against injected alternatives like ipamorelin and sermorelin.
What Is MK-677?
MK-677 (generic name: ibutamoren, also listed in research literature as MK-0677 and L-163,191) is a synthetic small molecule originally developed by Merck in the 1990s. The "peptide" label gets used loosely , MK-677 is actually a non-peptide compound with a sulfonamide backbone. That distinction matters. Peptides get broken down in the gut before they can absorb; MK-677's chemical structure bypasses that problem entirely, achieving oral bioavailability exceeding 60%.
It works by mimicking ghrelin , the hunger hormone. Specifically, MK-677 binds to the growth hormone secretagogue receptor subtype 1a (GHS-R1a) in the hypothalamus and anterior pituitary. When that receptor fires, the pituitary releases growth hormone in pulses , the same natural, pulsatile pattern your body uses overnight. GH then signals the liver to produce IGF-1 (insulin-like growth factor-1), and it's IGF-1 that drives most of the downstream effects on muscle, fat, and bone.
This is the key mechanistic difference from GHRH analogs like sermorelin or CJC-1295. Those compounds work upstream , they stimulate the GHRH receptor to tell the pituitary to prepare for GH release. MK-677 pulls the actual trigger directly. The two mechanisms are synergistic, which is why stacking MK-677 with a GHRH analog (in theory) produces stronger GH output than either alone.
Its 24-hour pharmacological action, with once-daily dosing aligning the peak effect window with the body's natural nocturnal GH pulse, is one reason it became so popular for body composition and sleep quality use.
Is MK677 a Supplement or a Drug?
Short answer: an MK677 supplement is not a true dietary supplement. The compound is sold in capsule and liquid form and marketed alongside supplements online, but MK677 is an investigational compound, not a vitamin, mineral, or herbal extract. It is not classified or approved as a dietary supplement under FDA rules.
What that means in practice: any MK677 supplement you buy is sold for personal use under the gray area that surrounds research-grade compounds. Vendors selling MK-677 cannot legally market it for human consumption, even when the packaging looks supplement-like. Anyone using it is taking on the same risk profile as any non-approved compound, which is why the side effect table below matters more than usual.
MK-677 Benefits
Lean Mass Preservation
A 12-month trial in healthy elderly subjects showed +1.1 kg fat-free mass in the MK-677 group versus −0.5 kg in placebo , meaningful in a population where muscle loss is the norm.
Metabolic Rate Increase
A transient 15% increase in basal metabolic rate was documented within 2 weeks of starting 25mg/day in obese subjects. The effect moderated over time but supported net energy expenditure.
Sleep Quality
In a 1997 Copinschi study, MK-677 increased Stage IV (deep) sleep by 50% and REM sleep by 20% in young adults. In older adults, REM sleep increased by nearly 50% and sleep deviations dropped from 42% to 8%.
Bone Turnover
Multiple trials confirmed MK-677 accelerates bone remodeling , osteocalcin up 15%, bone-specific alkaline phosphatase up 10.4%, bone formation markers elevated 39-45% within 6-8 weeks.
Anti-Catabolic Effect
Murphy et al. (1998) showed that 25mg/day reversed diet-induced nitrogen wasting in healthy men, shifting nitrogen balance from −2.67g/day to +0.31g/day while placebo remained at −1.48g/day.
GH Restoration in Aging
Chapman et al. (1996) showed that daily MK-677 in elderly subjects (64-81 years) increased 24-hour mean GH by 97% and restored IGF-1 concentrations to young adult levels within weeks.
What doesn't show up in the trials: dramatic fat loss. GH elevation helps shift body composition, but MK-677's fat loss effects in clinical data are modest and not consistently demonstrated across populations. If fat loss is the primary goal, the evidence is weaker than the community narrative suggests. Lean mass preservation and sleep quality are the areas with the most reliable signal.
MK-677 Dosage Guide
| Goal | Dose | Timing | Duration |
|---|---|---|---|
| Conservative start | 10-12.5mg/day | Bedtime, empty stomach | Weeks 1-2 |
| Standard protocol | 25mg/day | Bedtime, empty stomach | Weeks 3-12 |
| Sleep optimization | 25mg/day | 30-45 min before bed | 8-12 weeks |
| Body composition | 25mg/day | Bedtime | 8-12 weeks |
Every published human trial that showed meaningful results used 25mg/day. There's no strong evidence that going higher (50mg is sometimes used) produces proportionally better outcomes , and side effects including water retention, appetite, and glucose elevation scale up with dose. 10-12.5mg is a reasonable starting point to assess individual response, particularly around sleep disruption and hunger.
Cycle Length
8-12 weeks on, followed by a 4-8 week break. Preclinical rat data showed counter-regulatory adaptation , the brain increases somatostatin (the GH brake signal) with prolonged use, potentially blunting the GH response over time. Whether this happens at the same rate in humans isn't fully characterized, but it's a reasonable basis for cycling. Most experienced users run 12 weeks on, 6-8 weeks off.
For a more detailed protocol breakdown, see our ipamorelin dosage guide , the dosing principles overlap significantly for GH secretagogue timing and cycling.
MK 677 Side Effects
The MK 677 side effects below come from clinical trial data and consistent community reports. Most are predictable, dose-dependent, and reversible once the compound is stopped. The table groups them by how often they show up and when to stop dosing.
| Severity | Side effect | What it feels like | When to stop or pull back |
|---|---|---|---|
| Common (>20% in trials) | Water retention and edema | Puffy hands and face, mild ankle swelling, tight rings, 2 to 5 lb scale jump in the first 2 weeks | Usually subsides by week 3 to 4. Cut sodium first. Pull back the dose if it doesn't settle. |
| Common | Increased appetite | Sharp ghrelin-driven hunger, hardest at night, breaks any cut | Manage with timing and food choices. Stop only if it's pushing you out of a deficit you need to hold. |
| Common (20 to 30%) | Fatigue and lethargy | Daytime drowsiness, harder mornings, deeper sleep at night | Move dose to bedtime. If unmanageable, halve the dose for 7 days then reassess. |
| Common | Fasting glucose elevation | 5 to 15 mg/dL rise in fasting glucose; no symptoms in most | Stop if fasting glucose crosses 110 mg/dL or HbA1c climbs by more than 0.3% on cycle. |
| Less common | Tingling or numbness in hands and feet | Mild carpal tunnel-style symptoms tied to fluid retention and IGF-1 | Lower the dose. If symptoms persist beyond 2 weeks at the lower dose, stop. |
| Less common | Joint aches and stiffness | Wrist and finger stiffness, similar to high-IGF-1 states | Lower the dose. Usually resolves within a week. |
| Less common | Vivid dreams or insomnia at high dose | Intense dream activity early, sometimes broken sleep at 25 mg+ | Drop to 10 to 15 mg. If sleep doesn't improve in 5 to 7 days, stop. |
| Rare but serious | Cardiac strain (in already-vulnerable users) | Trial of GH-deficient adults: 4 of 62 (6.5%) developed congestive heart failure vs 1 of 60 placebo | Do not use at all if you have any history of heart disease, heart failure, or arrhythmia. |
| Rare | New-onset diabetes signs | Polyuria, polydipsia, sustained high fasting glucose | Stop immediately and get bloodwork. |
Stop MK-677 if any of these happen
- Fasting glucose stays above 110 mg/dL on two readings 48 hours apart
- HbA1c rises by more than 0.3% during a cycle
- Any chest pressure, shortness of breath, or new arrhythmia
- Edema does not resolve within 4 weeks at a lower dose
- Numbness or tingling in hands and feet persists at the lower dose
What MK-677 Does NOT Do
MK-677 does not suppress testosterone or natural hormone production at standard doses (up to 20 mg/day, and likely at 25 mg in most users). It's not a SARM, not a steroid, and doesn't require PCT. A case report cited 85.7% testosterone suppression, but that involved co-administration with LGD-4033, a SARM that is profoundly suppressive on its own. The SARM did the damage. Don't conflate the compounds.
MK-677 vs Ipamorelin vs Sermorelin
| Factor | MK-677 | Ipamorelin | Sermorelin |
|---|---|---|---|
| Administration | Oral tablet/capsule | Subcutaneous injection | Subcutaneous injection |
| Mechanism | Ghrelin receptor agonist (GHS-R1a) | Ghrelin receptor agonist (GHS-R1a) | GHRH receptor agonist |
| Half-life | ~4-6 hours (once daily effective) | ~2 hours | ~10-20 minutes |
| IGF-1 elevation | 40-72% (sustained) | Moderate, pulsatile | Moderate, pulsatile |
| GH pattern | Pulsatile, preserved rhythm | Pulsatile, selective | Pulsatile, natural timing |
| Appetite increase | Significant (ghrelin effect) | Minimal (selective receptor) | Minimal |
| Water retention | Moderate-high | Low | Low |
| Cortisol/prolactin effects | Generally minimal | Minimal (selective) | Minimal |
| Clinical trial data | Extensive (1996-2008) | Limited | Moderate |
| Best for | Oral dosing preference, sleep, anti-aging | Clean GH pulse, minimal sides | Natural GH support, anti-aging |
Ipamorelin and MK-677 technically work through the same receptor , but ipamorelin is a peptide with high selectivity and no appetite effect, while MK-677's non-peptide structure and lower receptor selectivity explains the hunger. If you hate needles, MK-677 is compelling. If you want the cleanest GH pulse without hunger or water retention, ipamorelin (especially stacked with CJC-1295) is the better option. See our ipamorelin/CJC-1295 dosage guide for that protocol.
For a broader look at where MK-677 fits in the GH peptide ecosystem, our best growth hormone peptides guide covers the full lineup.
MK-677 Results: What to Expect
Realistic timelines matter here. The community hype around MK-677 often overpromises , clinical data tells a more nuanced story.
| Timeline | What Research Shows | Common Reports |
|---|---|---|
| Week 1-2 | GH pulses increase; IGF-1 begins rising; 15% BMR elevation at 2 weeks | Better sleep, vivid dreams, increased hunger, early water retention |
| Week 2-4 | IGF-1 stabilizes at elevated levels; sleep architecture improvements continue | Improved recovery, fuller muscles, skin/hair changes beginning |
| Week 4-8 | Fat-free mass begins accruing; bone turnover markers elevated 39-45% | Noticeable body composition changes, strength improvements |
| Week 8-12 | 1.1 kg average fat-free mass gain over 12 months (extrapolates to ~0.5-0.7 kg at 8-12 weeks) | Maximum lean mass, continued sleep benefits, hunger often moderated |
The honest version: MK-677 is not a body recomposition shortcut. The 1.1 kg fat-free mass gain over 12 months in the Nass et al. trial is real but modest. What tends to be more notable for users is the sleep quality improvement , which has downstream effects on recovery and overall wellbeing that compound over time. People who use it primarily for the sleep benefits often report it as the best ROI of any GH-related compound they've tried.
Fat loss specifically is where MK-677 often disappoints relative to expectations. GH does promote lipolysis, but appetite stimulation from the ghrelin mechanism often offsets it unless diet is tightly controlled. Don't expect to lose fat on MK-677 without disciplined eating.
💡 Managing the Hunger
The ghrelin receptor activation means increased appetite is largely unavoidable. High-protein, high-fiber foods blunt hunger signals better than carb-heavy approaches. Some users front-load meals earlier in the day and take MK-677 just before bed to minimize waking hunger.
Where to Buy MK-677 for Research
MK-677 is sold as a research compound by numerous online vendors. Quality varies dramatically. The FDA has explicitly prohibited its sale as a dietary supplement , so anything marketed as a "supplement" is making an illegal claim. Legitimate research compound vendors sell it clearly labeled for laboratory research only, with third-party CoA documentation.
What to look for in a vendor:
- Certificate of Analysis (CoA) , From a third-party lab, showing compound identity and purity ≥98%
- HPLC testing , High-performance liquid chromatography confirms the compound is actually MK-677, not a filler
- Heavy metal testing , Community reports have flagged contamination in some market products; this matters
- Batch numbers and expiration dates , Basic quality indicators for any research compound
- No supplement claims , If they call it a "supplement" or claim health benefits on the label, that's a red flag
The Injectable GH Secretagogue Alternative
Ascension Peptides doesn't carry MK-677, but they do carry the FIT Stack (CJC-1295 + Ipamorelin) , which many researchers prefer for its cleaner side effect profile. The combination works through complementary mechanisms: CJC-1295 activates the GHRH receptor while ipamorelin fires the same GHS-R1a receptor as MK-677, producing synergistic GH pulses without appetite stimulation or the water retention typically seen with MK-677.
If needles aren't a dealbreaker, the FIT Stack often produces comparable or better body composition outcomes with fewer side effects. Our full guide on CJC-1295 + Ipamorelin protocols covers it in depth.
For a broader understanding of peptide therapy options, check out our peptide therapy guide.